Overview

Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects

Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to explore the safety and tolerability of MEDI-573 in Japanese subjects with advanced solid tumours refractory to standard therapy or for which no standard therapy exists.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Collaborator:
MedImmune LLC